

Remarks

This correspondence respectfully requests that the specification and the claims be amended from those previously amended under PCT Article 34 and Rule 66 in the above-identified application.

Applicant has amended the claims in this preliminary amendment under 37 CFR §1.115 which is being submitted simultaneously with this national patent application (PCT/IB2005/000016) under 35 USC §371. Please amend the present application as set forth in the Section entitled "Claims". In the present application, Claims 2, and 13-17 have been canceled. Claims 1, 3, 6, 8-9, 12, 18, 20-21, and 23 are currently amended to remove multiple dependencies. Further, Claim 1 was amended to include the limitation of a pharmaceutically acceptable salt. Claims 4-5, 7, 10-11, and 19 are original claims, as previously amended through the IPEA under PCT Article 34 and Rule 66. Claim 22 is new. Applicant submits that the amendments are fully supported by the specification as originally filed, and no new subject matter has been entered. Applicant respectfully requests entry of the amendment and examination on the merits.

Please amend the present application as set forth in the Section entitled "Amendment to the Specification". In accordance with 35 U.S.C. §119(e)(1) and 35 U.S.C. §120, the Applicants have submitted an amendment to the specification under 35 U.S.C. §371, PCT/IB2005/000016, filed January 3, 2005 which claims benefit of priority to Great Britain Provisional application 0400699.5 filed January 13, 2004 and US provisional application filed 60/545,554 February 17, 2004.